Tags

Type your tag names separated by a space and hit enter

Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.

Abstract

The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.

Authors+Show Affiliations

,

Division of Infectious Disease and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. FGH@Virginia.edu

, , , , , , , , ,

Source

Antiviral therapy 10:8 2005 pg 873-7

MeSH

Acetamides
Computer Communication Networks
Drug Resistance, Viral
Enzyme Inhibitors
Guanidines
Humans
Influenza A Virus, H5N1 Subtype
Influenza, Human
Neuraminidase
Oseltamivir
Pyrans
Sialic Acids
Viral Matrix Proteins
Zanamivir

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16430192

Citation

Hayden, Frederick, et al. "Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses." Antiviral Therapy, vol. 10, no. 8, 2005, pp. 873-7.
Hayden F, Klimov A, Tashiro M, et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther (Lond). 2005;10(8):873-7.
Hayden, F., Klimov, A., Tashiro, M., Hay, A., Monto, A., McKimm-Breschkin, J., ... Zambon, M. (2005). Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy, 10(8), pp. 873-7.
Hayden F, et al. Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. Antivir Ther (Lond). 2005;10(8):873-7. PubMed PMID: 16430192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. AU - Hayden,Frederick, AU - Klimov,Alexander, AU - Tashiro,Masato, AU - Hay,Alan, AU - Monto,Amold, AU - McKimm-Breschkin,Jennifer, AU - Macken,Catherine, AU - Hampson,Alan, AU - Webster,Robert G, AU - Amyard,Michèle, AU - Zambon,Maria, PY - 2006/1/25/pubmed PY - 2006/2/24/medline PY - 2006/1/25/entrez SP - 873 EP - 7 JF - Antiviral therapy JO - Antivir. Ther. (Lond.) VL - 10 IS - 8 N2 - The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner. SN - 1359-6535 UR - https://www.unboundmedicine.com/medline/citation/16430192/Neuraminidase_inhibitor_susceptibility_network_position_statement:_antiviral_resistance_in_influenza_A/H5N1_viruses_ L2 - https://medlineplus.gov/birdflu.html DB - PRIME DP - Unbound Medicine ER -